Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

– Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 – – Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, a

Cybin to Participate at the 27th Annual Milken Institute Global Conference

– Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 – TORONTO–(BUSINESS WIRE)–  Cybin Inc.  (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

TORONTO–(BUSINESS WIRE)–  Cybin Inc.  (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced

Announces Oversubscribed Private Placement of U.S. $150 Million

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO–(BUSINESS WIRE)–  Cybin Inc.  (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a